Last updated: 2026-10-02 05:55:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Attovia Therapeutics, Inc. (ATTO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $17.84, with a market capitalization of $829.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.15 to $28.00. This page covers its latest market performance, valuation, price trends and company information.
$829.03M | |
$17.26 | |
$73.60 | |
$0.42 | |
$17.14 | |
364.63K | |
456.27K | |
-- | |
$28.00 | |
$16.15 | |
-- | |
-- |
Attovia Therapeutics, Inc. (ATTO) last closed at $17.14 as of 2026-10-01 23:31:00, unchanged from the previous close of $17.14.
During the latest regular trading session, ATTO traded between $0.42 and $73.60, with a volume of 364.63K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Attovia Therapeutics, Inc. (ATTO) moved from $20.83 to $17.84, representing a decline of 14.34% ($2.99).
The stock traded between $16.62 and $21.73 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 552.18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 14.3%
ATTO is currently trading at $17.84, placing it 14.3% of the way from its 52-week low of $16.15 to its 52-week high of $28.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Attovia Therapeutics, Inc. (ATTO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.